Use of idarucizumab for emergency surgery in patients taking dabigatran
Open Access
- 22 January 2022
- journal article
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 11 (2), 76-86
- https://doi.org/10.21518/2307-1109-2021-11-2-76-86
Abstract
This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate. We describe two clinical situations, in which idarucizumab, a specific dabigatran antagonist, which is a monoclonal antibody fragment that binds dabigatran, was used to neutralize the anticoagulant effect of dabigatran etexilate before emergency surgery. In the first case, the patient developed acute gangrenous calculous cholecystitis, in the second a patient required an urgent epicystostomy. In both cases, the successful outcome of surgical interventions was due to the effective interactions of the team of specialists and adherence to the algorithm for providing emergency care to such patients, as well as the presence of idarucizumab in hospitals. The postoperative management of patients and the timely resumption of anticoagulant therapy to prevent thromboembolic complications is no less important. The presented clinical cases confirm the feasibility of using idarucizumab to provide emergency surgical care to patients on dabigatran etexilate, as well as the need to take into account the possible risk of emergency interventions when anticoagulant therapy is prescribed to patients with atrial fibrillation. This paper discusses special risk groups of patients in whom rapid reversal of anticoagulation is required due to altered hemostasis.We outline data of a prospective cohort study (RE-VERSE AD), which examined the efficacy and safety of idarucizumab in patients with uncontrolled bleeding and in patients requiring urgent surgery. We also present the RE-VECTO study data on the use of idarucizumab in real-life clinical practice.Keywords
This publication has 21 references indexed in Scilit:
- Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyJournal of Medical Economics, 2017
- Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocolsThe American Journal of Emergency Medicine, 2016
- Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trialThe Lancet Neurology, 2016
- A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThrombosis and Haemostasis, 2015
- Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trialThe Lancet, 2015
- Comparing mortality in patients with atrial fibrillation who are receiving a direct‐acting oral anticoagulant or warfarin: a meta‐analysis of randomized trialsJournal of Thrombosis and Haemostasis, 2014
- Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: A systematic reviewThrombosis Research, 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major BleedingJournal of the American College of Cardiology, 2013
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009